Balance Sheet
Accounts PayablesAccumulated ExpensesCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwill & IntangiblesInventoryLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zhengye Biotechnology Holding (ZYBT) Receivables - Net: 2023-2025

  • Zhengye Biotechnology Holding's Receivables - Net was N/A to $5.1 million in Q2 2025 from the same period last year, while for Jun 2025 it was $5.1 million, marking a year-over-year change of. This contributed to the annual value of $10.6 million for FY2024, which is 18.97% down from last year.
  • Per Zhengye Biotechnology Holding's latest filing, its Receivables - Net stood at $5.1 million for Q2 2025, which was down 51.23% from $10.5 million recorded in Q4 2024.
  • Zhengye Biotechnology Holding's 5-year Receivables - Net high stood at $12.9 million for Q4 2023, and its period low was $5.1 million during Q2 2025.
  • Moreover, its 3-year median value for Receivables - Net was $10.5 million (2024), whereas its average is $9.5 million.
  • Data for Zhengye Biotechnology Holding's Receivables - Net shows a maximum YoY fell of 18.74% (in 2024) over the last 5 years.
  • Zhengye Biotechnology Holding's Receivables - Net (Quarterly) stood at $12.9 million in 2023, then dropped by 18.74% to $10.5 million in 2024, then reached $5.1 million in 2025.
  • Its Receivables - Net stands at $5.1 million for Q2 2025, versus $10.5 million for Q4 2024 and $12.9 million for Q4 2023.